Central America (Costa Rica, Panama, Guatemala, Dominican Republic) Acute Myeloid Leukemia Drugs Market

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 OVERVIEW OF CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET 16
1.4 CURRENCY AND PRICING 18
1.5 LIMITATIONS 18
1.6 MARKETS COVERED 18
2 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 22
2.4 DBMR TRIPOD DATA VALIDATION MODEL 23
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 26
2.6 MULTIVARIATE MODELLING 27
2.7 SUB-TYPE SEGMENT LIFELINE CURVE 27
2.8 DBMR MARKET POSITION GRID 28
2.9 MARKET END USER COVERAGE GRID 30
2.10 SECONDARY SOURCES 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 35
4.1 EPIDEMIOLOGY 36
4.2 PESTEL'S MODEL 37
4.3 PORTER'S 5 FORCES 38
5 PIPELINE ANALYSIS FOR CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET 39
6 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA, AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: REGULATIONS 40

7 MARKET OVERVIEW 43
7.1 DRIVERS 45
7.1.1 RISE IN GERIATRIC POPULATION 45
7.1.2 RISING INVESTMENT IN RESEARCH AND DEVELOPMENT 45
7.1.3 RISING CLINICAL TRIALS AND PRODUCT APPROVAL 46
7.1.4 RISING INCIDENCE OF ACUTE MYELOID LEUKEMIA 46
7.2 RESTRAINTS 46
7.2.1 ADVERSE EFFECTS ASSOCIATED WITH ACUTE MYELOID LEUKEMIA DRUGS 46
7.2.2 HIGH COST OF CANCER MEDICINE 47
7.3 OPPORTUNITIES 47
7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 47
7.3.2 RISE IN HEALTHCARE EXPENDITURE 47
7.3.3 RISE OF INNOVATIVE THERAPIES 48
7.4 CHALLENGES 48
7.4.1 LACK OF SKILLED PROFESSIONALS 48
7.4.2 STRINGENT REGULATIONS 49
8 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE 50
8.1 OVERVIEW 51
8.2 M3 (ACUTE PROMYELOCYTIC LEUKEMIA (APL)) 54
8.3 M2 (ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION) 54
8.4 M4 (ACUTE MYELOMONOCYTIC LEUKEMIA) 55
8.5 M0 (UNDIFFERENTIATED ACUTE MYELOBASTIC LEUKEMIA) 55
8.6 M1 (ACUTE MYELOBLASTIC LEUKEMIA WITH MINIMAL MATURATION) 56
8.7 M5 (ACUTE MONOCYTIC LEUKEMIA) 56
8.8 M7 (ACUTE MEGAKARYOBLASTIC LEUKEMIA) 56
8.9 M6 (ACUTE ERYTHROID LEUKEMIA) 57
9 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS 58
9.1 OVERVIEW 59
9.2 CHEMOTHERAPY 62
9.2.1 CYTARABINE (CYTOSAR) 63
9.2.2 DAUNORUBICIN 63
9.2.3 DOXORUBICIN 63
9.2.4 METHOTREXATE 63
9.2.5 DECITABINE 63
9.2.6 CLADRIBINE 63
9.2.7 OTHERS 63
9.3 TARGETED THERAPY 63
9.3.1 VENETOCLAX (VENCLEXTA) 64
9.3.2 MIDOSTAURIN (RYDAPT) 64
9.3.3 ENASIDENIB (IDHIFA) 64
9.3.4 OTHERS 65
9.4 IMMUNOTHERAPY 65
9.4.1 OBINUTUZUMAB (GAZYVA/GAZYVARO) 65
9.4.2 RITUXIMAB 66
9.4.3 INTERFERONS 66
9.4.4 ALEMTUZUMAB (CAMPATH) 66
9.4.5 OTHERS 66
10 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE 67
10.1 OVERVIEW 68
10.2 BRANDED 71
10.2.1 CYTOSAR 71
10.2.2 VENCLEXTA 72
10.2.3 RYDAPT 72
10.2.4 IDHIFA 72
10.2.5 GAZYVA/GAZYVARO 72
10.2.6 CAMPATH 72
10.2.7 OTHERS 72
10.3 GENERICS 72
11 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION 73
11.1 OVERVIEW 74
11.2 PARENTERAL 77
11.2.1 INTRAVENOUS 77
11.2.2 SUBCUTANEOUS 77
11.2.3 OTHERS 77
11.3 ORAL 78
11.3.1 TABLET 78
11.3.2 CAPSULE 78
11.3.3 OTHERS 79
11.4 OTHERS 79
11 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE 80
11.3 OVERVIEW 81
11.4 GERIATRIC 84
11.5 ADULTS 84
11.5.1 MALE 85
11.5.2 FEMALE 85
11.6 PEDIATRIC 85
12 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER 86
12.3 OVERVIEW 87
12.4 HOSPITALS 90
12.5 SPECIALTY CLINICS 90
12.6 AMBULATORY CENTERS 90
12.7 OTHERS 91
13 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL 92
13.1 OVERVIEW 93
13.2 DIRECT TENDER 96
13.3 HOSPITAL PHARMACY 96
13.4 RETAIL PHARMACY 96
13.5 ONLINE PHARMACY 97
13.6 OTHERS 97
14 CENTRAL AMERICA AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY COUNTRY 98
14.1 COSTA RICA 105
14.2 PANAMA 110
14.3 DOMINICAN REPUBLIC 115
14.4 GUATEMALA 120
14.5 REST OF CENTRAL AMERICA 125

15 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) MARKET: COMPANY LANDSCAPE 126
15.1 COMPANY SHARE ANALYSIS: CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) 126
16 SWOT ANALYSIS 127
17 COMPANY PROFILE 128
17.1 PFIZER INC. 128
17.1.1 COMPANY SNAPSHOT 128
17.1.2 REVENUE ANALYSIS 128
17.1.3 PRODUCT PORTFOLIO 129
17.1.4 RECENT DEVELOPMENT 129
17.2 ABBVIE INC. 130
17.2.1 COMPANY SNAPSHOT 130
17.2.2 REVENUE ANALYSIS 130
17.2.3 PRODUCT PORTFOLIO 131
17.2.4 RECENT DEVELOPMENTS 131
17.3 NOVARTIS AG 132
17.3.1 COMPANY SNAPSHOT 132
17.3.2 REVENUE ANALYSIS 132
17.3.3 PRODUCT PORTFOLIO 133
17.3.4 RECENT DEVELOPMENT 133
17.4 BRISTOL-MYERS SQUIBB COMPANY 134
17.4.1 COMPANY SNAPSHOT 134
17.4.2 REVENUE ANALYSIS 134
17.4.3 PRODUCT PORTFOLIO 135
17.4.4 RECENT DEVELOPMENT 135
17.5 F.HOFFMAN-LA ROCHE LTD 136
17.5.1 COMPANY SNAPSHOT 136
17.5.2 REVENUE ANALYSIS 136
17.5.3 PRODUCT PORTFOLIO 137
17.5.4 RECENT DEVELOPMENT 137
17.6 ASTRAZENECA 138
17.6.1 COMPANY SNAPSHOT 138
17.6.2 REVENUE ANALYSIS 138
17.6.3 PRODUCT PORTFOLIO 139
17.6.4 RECENT DEVELOPMENT 139

17.7 BOHRINGER INGELHEIM INTERNATIONAL GMBH 140
17.7.1 COMPANY SNAPSHOT 140
17.7.2 REVENUE ANALYSIS 140
17.7.3 PRODUCT PORTFOLIO 141
17.7.4 RECENT DEVELOPMENT 141
17.8 FRESENIUS KABI AG 142
17.8.1 COMPANY SNAPSHOT 142
17.8.2 REVENUE ANALYSIS 142
17.8.3 PRODUCT PORTFOLIO 143
17.8.4 RECENT DEVELOPMENT 143
17.9 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 144
17.9.1 COMPANY SNAPSHOT 144
17.9.2 REVENUE ANALYSIS 144
17.9.3 PRODUCT PORTFOLIO 145
17.9.4 RECENT DEVELOPMENTS 145
17.10 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) 146
17.10.1 COMPANY SNAPSHOT 146
17.10.2 REVENUE ANALYSIS 146
17.10.3 PRODUCT PORTFOLIO 147
17.10.4 RECENT DEVELOPMENT 147
17.11 SUN PHARMACEUTICAL INDUSTRIES LTD. 148
17.11.1 COMPANY SNAPSHOT 148
17.11.2 REVENUE ANALYSIS 148
17.11.3 PRODUCT PORTFOLIO 149
17.11.4 RECENT DEVELOPMENT 149
17.12 TEVA PHARMACEUTICAL INDUSTRIES LTD 150
17.12.1 COMPANY SNAPSHOT 150
17.12.2 REVENUE ANALYSIS 150
17.12.3 PRODUCT PORTFOLIO 151
17.12.4 RECENT DEVELOPMENT 151
17.13 VIATRIS INC. 152
17.13.1 COMPANY SNAPSHOT 152
17.13.2 REVENUE ANALYSIS 152
17.13.3 PRODUCT PORTFOLIO 153
17.13.4 RECENT DEVELOPMENTS 153
18 QUESTINNAIRE 154
19 RELATED REPORTS 158